Gedeon Richter provides updated guidance for Kvamatel medication

Gedeon Richter Plc. has released updated product information for its Kvamatel tablets, which contain the active ingredient famotidine. As an H2-receptor antagonist, the medication is primarily utilized to reduce gastric acid secretion in adult patients suffering from peptic ulcers, gastroesophageal reflux disease, and other hypersecretory conditions.

The updated documentation highlights the drug's role in preventing gastric juice aspiration during anesthesia while reinforcing the necessity of medical supervision. Patients with existing hepatic or renal impairment are advised to exercise caution, as clinical adjustments in dosage may be required to prevent potential complications.

Safety data indicates potential drug-drug interactions, particularly regarding medications that depend on gastric pH levels for absorption, such as certain antifungals and HIV treatments. Use in patients under 18 years of age is not currently recommended due to insufficient clinical data regarding safety and efficacy.

The company emphasizes that regular monitoring of blood counts and liver function is advised for patients undergoing long-term, high-dose treatment.